Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed <i>IDH1</i> -mutated AML
Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study
<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial
QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in <i>FLT3</i> -ITD–negative acute myeloid leukemia (AML).
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024)
Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia
CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis
This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial
Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity
Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, <i>FLT3</i>-ITD-Negative Acute Myeloid Leukemia
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma
CACA guidelines for holistic integrative management of adult acute myeloid leukemia
Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
Dry eye disease caused by viral infection: Past, present and future
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
Immunophenotype distinctions of <scp><i>CEBPA</i></scp> mutation subtypes in acute myeloid leukemia
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) <i>FLT3</i>-ITD+ AML Patients (pts)
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL